{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:39:11Z","timestamp":1793659151081,"version":"4.5.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":125,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Basel Research Fund for Excellent Junior Researchers","award":["3MS1090"],"award-info":[{"award-number":["3MS1090"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Predicting early treatment failure in glioblastoma remains challenging. Given the median survival of 13.5 months, better prognostic biomarkers are needed. This study aimed to identify predictors of early treatment failure and their association with overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective analysis of consecutive patients with newly diagnosed glioblastoma who underwent DSC- and DCE-MRI before surgery and radiochemotherapy. Treatment failure was defined as tumor progression per RANO 2.0 criteria within 6 months of surgery. Factors independently associated with outcome among clinical, MRI perfusion at the diagnosis and molecular parameters were identified using multivariable logistic regression models. OS was evaluated using a 180-day landmark analysis to avoid time-dependent bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 62 patients diagnosed between 01\/2017 and 12\/2021, 44 patients (71%) were non-responders and 18 patients (29%) responders. Elevated pretreatment rCBV and Ktrans were associated with treatment response (P\u2009&amp;lt;\u2009.05), with non-responders showing lower median rCBV (4.15 vs 5.90) and Ktrans (0.15 vs 0.17 min\u22121). A model, including age, perfusion metrics, and MGMT methylation status showed robust discrimination (AUC\u2009=\u20090.84, 95% CI: [0.73; 0.95]) to identify non-responders. Landmark analysis showed no evidence for early treatment failure itself to be associated with OS (P\u2009=\u2009.40), whereas MGMT promoter methylation status was associated with long-term survival and reduced hazard of death (HR: 0.31, 95% CI: 0.17-0.55; P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pretreatment MRI perfusion metrics may predict short-term treatment failure and may guide early experimental therapy, while the MGMT status remains the primary determinant of long-term survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag119","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:20:30Z","timestamp":1777638030000},"source":"Crossref","is-referenced-by-count":1,"title":["Prediction of treatment failure in patients with glioblastoma with perfusion MRI and molecular biomarkers"],"prefix":"10.1093","volume":"8","author":[{"given":"Riccardo","family":"Ludovichetti","sequence":"first","affiliation":[{"name":"Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Villiers","sequence":"additional","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3986-9844","authenticated-orcid":false,"given":"Gergely","family":"Bertalan","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-7387","authenticated-orcid":false,"given":"Nicolin","family":"Hainc","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-3400","authenticated-orcid":false,"given":"Andrea","family":"Bink","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-3278","authenticated-orcid":false,"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich , Zurich,","place":["Switzerland"]},{"name":"Department of Neurorehabilitation, Clinic Lengg , Zurich, (E.L.R.)","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3105-5840","authenticated-orcid":false,"given":"Ulrike","family":"Held","sequence":"additional","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6805-5150","authenticated-orcid":false,"given":"Zsolt","family":"Kulcsar","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4650-8312","authenticated-orcid":false,"given":"Ramona-Alexandra","family":"Todea","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]},{"name":"University of Basel , Basel,","place":["Switzerland"]},{"name":"Division of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital of Basel , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026052703320599600_vdag119-B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018\u20132022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026052703320599600_vdag119-B2","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1259\/bjr\/83796755","article-title":"A clinical review of treatment outcomes in glioblastoma multiforme\u2014the validation in a non-trial population of the results of a randomised phase III clinical trial: has a more radical approach improved survival?","volume":"85","author":"Rock","year":"2012","journal-title":"Br J Radiol"},{"key":"2026052703320599600_vdag119-B3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12032-025-02830-1","article-title":"Unlocking glioblastoma: breakthroughs in molecular mechanisms and next-generation therapies","volume":"42","author":"Rizwani","year":"2025","journal-title":"Med Oncol"},{"key":"2026052703320599600_vdag119-B4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026052703320599600_vdag119-B5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/annonc\/mdy106","article-title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study","volume":"29","author":"Gramatzki","year":"2018","journal-title":"Ann Oncol"},{"key":"2026052703320599600_vdag119-B6","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other Central nervous system tumors diagnosed in the United States in 2014-2018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026052703320599600_vdag119-B7","doi-asserted-by":"publisher","first-page":"112913","DOI":"10.1016\/j.ejca.2023.05.002","article-title":"Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY brain tumor funders\u2019 collaborative consortium (EORTC 1419)","volume":"189","author":"Hertler","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026052703320599600_vdag119-B8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052703320599600_vdag119-B9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.5603\/RPOR.a2022.0113","article-title":"Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study","volume":"27","author":"Mohammed","year":"2022","journal-title":"Rep Pract Oncol Radiother"},{"key":"2026052703320599600_vdag119-B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"2026052703320599600_vdag119-B11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jnci\/djq497","article-title":"DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma","volume":"103","author":"Christensen","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2026052703320599600_vdag119-B12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/neuonc\/noac177","article-title":"DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients","volume":"25","author":"Drexler","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026052703320599600_vdag119-B13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1148\/radiol.10091461","article-title":"Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence","volume":"256","author":"Kim","year":"2010","journal-title":"Radiology"},{"key":"2026052703320599600_vdag119-B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40644-015-0039-z","article-title":"Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging","volume":"15","author":"Li","year":"2015","journal-title":"Cancer Imaging"},{"key":"2026052703320599600_vdag119-B15","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026052703320599600_vdag119-B16","doi-asserted-by":"publisher","first-page":"112234","DOI":"10.1016\/j.ejrad.2025.112234","article-title":"Treatment response assessment in glioblastoma with GRASP DCE-MRI","volume":"190","author":"Vankan","year":"2025","journal-title":"Eur J Radiol"},{"key":"2026052703320599600_vdag119-B17","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.neurad.2025.101354","article-title":"Differentiation of tumor progression from pseudoprogression in glioblastoma patients with GRASP DCE-MRI and DSC-MRI","volume":"52","author":"Var","year":"2025","journal-title":"J Neuroradiol"},{"key":"2026052703320599600_vdag119-B18","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ."},{"key":"2026052703320599600_vdag119-B19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/197140091302600404","article-title":"Correlation between cerebral blood volume measurements by perfusion-weighted magnetic resonance imaging and two-year progression-free survival in gliomas","volume":"26","author":"Spampinato","year":"2013","journal-title":"Neuroradiol J"},{"key":"2026052703320599600_vdag119-B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3174\/ajnr.A4474","article-title":"Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI","volume":"37","author":"Wang","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"2026052703320599600_vdag119-B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/jmri.26306","article-title":"Perfusion MRI in treatment evaluation of glioblastomas: clinical relevance of current and future techniques","volume":"49","author":"van Dijken","year":"2019","journal-title":"J Magn Reson Imaging"},{"key":"2026052703320599600_vdag119-B22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/156652409788167087","article-title":"Hypoxia and radiation therapy: past history, ongoing research, and future promise","volume":"9","author":"Rockwell","year":"2009","journal-title":"Curr Mol Med"},{"key":"2026052703320599600_vdag119-B23","doi-asserted-by":"publisher","first-page":"849993","DOI":"10.3389\/fonc.2022.849993","article-title":"Paradoxical association between relative cerebral blood volume dynamics following chemoradiation and increased Progression-Free survival in newly diagnosed IDH Wild-Type MGMT promoter methylated glioblastoma with measurable disease","volume":"12","author":"Goldman","year":"2022","journal-title":"Front Oncol"},{"key":"2026052703320599600_vdag119-B24","doi-asserted-by":"publisher","first-page":"19059","DOI":"10.1073\/pnas.1318022110","article-title":"Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation","volume":"110","author":"Batchelor","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026052703320599600_vdag119-B25","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2026052703320599600_vdag119-B26","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/neuonc\/nov198","article-title":"Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter\u2014still a dilemma?","volume":"17","author":"Hegi","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026052703320599600_vdag119-B27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00062-014-0289-3","article-title":"Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification","volume":"25","author":"Gupta","year":"2015","journal-title":"Clin Neuroradiol"},{"key":"2026052703320599600_vdag119-B28","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jmri.29781","article-title":"Imaging-Based molecular characterization of adult-type diffuse glioma using diffusion and perfusion MRI in pre- and Post-treatment stage considering spatial and temporal heterogeneity","volume":"62","author":"Roh","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"2026052703320599600_vdag119-B29","doi-asserted-by":"publisher","first-page":"110318","DOI":"10.1016\/j.mri.2024.110318","article-title":"Investigating glioma genetics through perfusion MRI: rCBV and rCBF as predictive biomarkers","volume":"117","author":"\u015aledzi\u0144ska-Bebyn","year":"2025","journal-title":"Magn Reson Imaging"},{"key":"2026052703320599600_vdag119-B30","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1016\/j.acra.2024.02.017","article-title":"Quantitative and qualitative parameters of DCE-MRI predict CDKN2A\/B homozygous deletion in gliomas","volume":"31","author":"Yang","year":"2024","journal-title":"Acad Radiol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag119\/68234267\/vdag119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag119\/68234267\/vdag119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag119\/68234267\/vdag119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:32:13Z","timestamp":1779867133000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag119\/8671357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag119","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag119"}}